A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of Single-and Multiple Ascending Doses of LY3478045in Healthy Subjects
Latest Information Update: 29 Jul 2024
At a glance
- Drugs LY 3478045 (Primary) ; Atorvastatin
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
Most Recent Events
- 12 Jul 2021 Status changed from active, no longer recruiting to completed.
- 07 Jun 2021 Status changed from recruiting to active, no longer recruiting.
- 17 Jul 2020 Status changed from suspended to recruiting.